Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Eadie

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Cancer Letters|November 10, 2019
KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk diseaseMichelle O Forgione, Barbara J McClure, Laura N Eadie, et al.
Leukemia|November 21, 2012
Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cellsD L White, L N Eadie, V A Saunders, et al.
Oncology Reports|March 24, 2022
<i>TP53</i> loss‑of‑function mutations reduce sensitivity of acute leukaemia to the curaxin CBL0137Michelle O Forgione, Barbara J McClure, Elyse C Page, et al.
British Journal of Cancer|December 4, 2019
The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALLPaniz Tavakoli Shirazi, Laura N Eadie, Susan L Heatley, et al.
Cancer Letters|May 10, 2021
Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemiaPaniz Tavakoli Shirazi, Laura N Eadie, Elyse C Page, et al.
Scientific Reports|August 11, 2023
The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associated with each resistance mechanismBenjamin C S Leow, Chung H Kok, David T Yeung, et al.
Cancer Gene Therapy|January 13, 2022
Exploring the oncogenic and therapeutic target potential of the MYB-TYK2 fusion gene in B-cell acute lymphoblastic leukemiaPaniz Tavakoli Shirazi, Laura N Eadie, Susan L Heatley, et al.
Leukemia|July 16, 2016
The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatmentL N Eadie, P Dang, V A Saunders, et al.
British Journal of Haematology|July 31, 2023
Case report: Rare case of donor cell-derived T-cell acute lymphoblastic leukaemia in a female patient after receiving an allo-transplant from her male siblingLaura N Eadie, Jacqueline A Rehn, Caitlin E Schutz, et al.
Plos Genetics|October 17, 2022
RaScALL: Rapid (Ra) screening (Sc) of RNA-seq data for prognostically significant genomic alterations in acute lymphoblastic leukaemia (ALL)Jacqueline Rehn, Chelsea Mayoh, Susan L Heatley, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Cancer Letters|November 10, 2019
KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk diseaseMichelle O Forgione, Barbara J McClure, Laura N Eadie, et al.
Leukemia|November 21, 2012
Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cellsD L White, L N Eadie, V A Saunders, et al.
Oncology Reports|March 24, 2022
<i>TP53</i> loss‑of‑function mutations reduce sensitivity of acute leukaemia to the curaxin CBL0137Michelle O Forgione, Barbara J McClure, Elyse C Page, et al.
British Journal of Cancer|December 4, 2019
The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALLPaniz Tavakoli Shirazi, Laura N Eadie, Susan L Heatley, et al.
Cancer Letters|May 10, 2021
Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemiaPaniz Tavakoli Shirazi, Laura N Eadie, Elyse C Page, et al.
Scientific Reports|August 11, 2023
The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associated with each resistance mechanismBenjamin C S Leow, Chung H Kok, David T Yeung, et al.
Cancer Gene Therapy|January 13, 2022
Exploring the oncogenic and therapeutic target potential of the MYB-TYK2 fusion gene in B-cell acute lymphoblastic leukemiaPaniz Tavakoli Shirazi, Laura N Eadie, Susan L Heatley, et al.
Leukemia|July 16, 2016
The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatmentL N Eadie, P Dang, V A Saunders, et al.
British Journal of Haematology|July 31, 2023
Case report: Rare case of donor cell-derived T-cell acute lymphoblastic leukaemia in a female patient after receiving an allo-transplant from her male siblingLaura N Eadie, Jacqueline A Rehn, Caitlin E Schutz, et al.
Plos Genetics|October 17, 2022
RaScALL: Rapid (Ra) screening (Sc) of RNA-seq data for prognostically significant genomic alterations in acute lymphoblastic leukaemia (ALL)Jacqueline Rehn, Chelsea Mayoh, Susan L Heatley, et al.
Pageof 3